PDRN vs Polynucleotides: Understanding PN and PDRN

The short answer

PDRN and PN are related materials, not cleanly separate ingredient families. The dermatology comparison review describes both as DNA-derived biopolymers, with PDRN generally containing shorter chains and PN longer chains. The narrative dermatology review also calls PDRN a subset of the broader polynucleotide category. That makes PDRN vs Polynucleotides partly a question of terminology, rather than a simple contest between unrelated treatments.

The names are used inconsistently, according to the molecular-definition review. Its authors report that PDRN and PN have been used interchangeably for polymers of varying lengths, creating confusion in scientific and medical settings. They propose a molecular-weight cutoff to make the distinction clearer. A proposed definition, however, does not establish that every cosmetic label or clinic menu follows it.

Neither acronym establishes which treatment will work better for your skin. The PN systematic review reports promising injection results but calls for stronger studies; the PDRN cell study investigates mechanisms, not a finished serum. For the ingredient basics, see what PDRN is. Keep the material, delivery route, and supporting study separate when comparing products.

Sources: [1] [3] [7] [9] [10]

How they differ chemically

Chain length and molecular weight are the main chemical distinctions described in the comparison review. It says PN typically contains relatively longer DNA chains derived from fish testes, including salmon or trout, while PDRN generally contains shorter chains extracted from fish sperm. The narrative dermatology review adds that polynucleotides can come from DNA or RNA, although the materials discussed are usually DNA-derived.

The proposed dividing line is 1500 kDa, according to the molecular-definition review. Its authors suggest reserving PDRN for small- and medium-chain polymers below that threshold and PN for longer-chain polymers at or above it. They call this the Marques Polynucleotide Cutoff. The comparison review separately says terminology still needs clarification, so treat the threshold as a naming proposal, not a universal label rule.

The materials also differ in physical behavior, according to the comparison review. It describes PDRN as having lower viscoelasticity, while PN forms a more porous, highly viscous three-dimensional structure. The review describes PN forming a hydrogel that supports hydration and skin viscosity. These properties help explain the distinction, but they do not establish that any particular PN product outperforms a PDRN product.

Fish origin is common, but it is not the only source described in the research. The narrative dermatology review identifies Korean ginseng adventitious roots as a plant source of PDRN and reports fibroblast findings for red-algae-derived PDRN. The acronym alone therefore does not settle origin. Our salmon DNA skincare guide covers the source terminology; a specific product still needs its own source information.

Sources: [1] [3] [9]

How clinics use each

Clinics describe PN skin boosters as injectable treatments aimed at skin quality rather than structural volume. Apex Medical says its polynucleotides stimulate repair and support collagen, elastin, and hydration; it lists the under-eyes, face, neck, and décolletage among treatment areas. These are the clinic's descriptions of its service, not independent proof that every PN formulation produces those outcomes.

PN and PDRN can appear under different treatment names, according to retailer Laboderm Skin. It describes Rejuran PN as used for anti-aging and rejuvenation, and Rejuvenex forte as used for scars, wound healing, fine wrinkles, and acne. It also says Rejuran HB includes hyaluronic acid and lidocaine. Those distinctions describe the retailer's product positioning, not a controlled comparison showing that PN or PDRN is superior.

Published clinic prices describe particular services, not a standard PN price. Apex Medical lists polynucleotide skin boosters from £500 and says the written consultation quote includes follow-up care. Laboderm Skin quotes approximately $250 USD for a Rejuran or Vitaran treatment using one 2 ml syringe, or approximately $200 USD during Korean clinic holiday promotions. These quotes do not establish equivalent products, protocols, or treatment settings.

Injection risks deserve more attention than the acronym. The Skin to Love Clinic lists bruising and swelling as possible adverse effects, while Harper's Bazaar reports that polynucleotide injections cannot be reversed by dissolving the product as dermal filler can. Discuss suitability, pregnancy, breastfeeding, fish allergies, and skin conditions with a board-certified dermatologist or licensed injector. Our PDRN injection guide provides related context.

Sources: [2] [4] [5] [6]

Evidence for skin

PN injections have promising human evidence, but its quality remains limited. The systematic review covered 219 patients and rated the included studies as low and moderate quality. It reported improvements in wrinkles, skin texture, and elasticity, with statistically significant results in several studies. Injection areas and techniques varied, and the authors concluded that rigorous, high-quality research is still needed to validate effectiveness and safety.

A controlled eye-area trial provides a narrower picture than broad rejuvenation claims. The randomized, double-blind, split-face study enrolled 27 subjects, comparing PN with non-crosslinked hyaluronic acid through three injection sessions at two-week intervals. It found no statistically significant difference on the visual analog or global esthetic improvement scales. Some measured outcomes favored PN, including improvement rates for elasticity, hydration, roughness, and pore volume; dermal-density improvement did not differ significantly.

PDRN's cell findings explain possible mechanisms, not a serum's visible results. The keratinocyte and fibroblast study found that PDRN promoted cell proliferation and migration. In fibroblasts, it increased ERK phosphorylation and collagen accumulation while inhibiting matrix metalloproteinase expression; in keratinocytes, it decreased inflammatory cytokine expression. The authors concluded that its mechanism differs between skin cell types. Those laboratory findings do not establish clinical benefits from applying a cosmetic.

The studies discussed here do not establish a PN-versus-PDRN winner for facial skincare. The eye-area trial compared PN with hyaluronic acid, not PDRN, while the PDRN mechanism study tested cells rather than patients using topical products. Comparable benefits from a serum are not established by those findings. Our research reference keeps these evidence categories separate: a plausible mechanism and an injection outcome are not interchangeable.

Sources: [7] [8] [10]

Reading labels and clinic menus

A PN or PDRN label does not, by itself, establish chain length or treatment performance. The molecular-definition review reports inconsistent naming and lists formulations spanning gels, creams, serums, masks, and injectables. When reading a label or menu, look for the exact product, delivery route, stated concentration, and accompanying ingredients. If molecular weight is not disclosed, the acronym alone does not reliably establish it.

A familiar brand name does not establish that a cosmetic is the same formulation used in a clinic. Laboderm Skin describes Rejuran Trueskin and Elaskin essences as export cosmetics with lower PN content, rather than the KFDA-approved Rejuran PN medical device. It lists standard Rejuran as containing 2% PN. Those are retailer statements about particular products, not a reason to transfer medical-device findings to a similarly named essence.

Claims about format and absorption need their own evidence. Laboderm Skin claims PN is only made as an injectable medical device and that PDRN is more easily absorbed topically. Yet the molecular-definition review describes PDRN/PN formulations across cosmetic and injectable formats. Given that naming inconsistency, polynucleotides vs PDRN on a menu is not enough to establish absorption, regulatory status, or effectiveness. Ask what exact formulation and supporting study the claim concerns.

Sources: [2] [9]